Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Life sciences is undervalued right now, says JMP Securities Mark Lehmann
05:17pm, Monday, 19'th Sep 2022
JMP Securities CEO Mark Lehmann joins 'Closing Bell: Overtime' to discuss why he likes health care stocks as the place to be right now.
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Tuesday, 06'th Sep 2022
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q2 2022 Results - Earnings Call Transcript
11:19am, Sunday, 07'th Aug 2022
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 AM ET Company Participants Diane Weiser - SVP, Corporate Communications and Investor Relations Robert Blu
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Thursday, 04'th Aug 2022
Cytokinetics (CYTK) delivered earnings and revenue surprises of 77.88% and 2,483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analyst Ratings for Cytokinetics
05:17pm, Friday, 15'th Jul 2022 Benzinga
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
2
0
0
0
Last 30D
Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering
07:35am, Friday, 01'st Jul 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., July 01, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $450.0 million aggregate
Cytokinetics Announces Proposed Convertible Senior Notes Offering
08:35pm, Wednesday, 29'th Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced its intention to offer, subject to market and other cond
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
11:30am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Meeting Currently Scheduled for December 13, 2022 Meeting Currently Scheduled for December 13, 2022
Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil
07:30am, Friday, 24'th Jun 2022
Meeting Currently Scheduled for December 13, 2022 Meeting Currently Scheduled for December 13, 2022
Cytokinetics Hopes to Emulate Vertex's Market Success, Share Price Gains
04:05pm, Thursday, 23'rd Jun 2022
If Cytokinetics Inc. ( CYTK , Financial) can come anywhere close to achieving its lofty ambition of becoming the Vertex Pharmaceuticals Inc. ( VRTX , Financial) of specialty cardiovascular drugs, shar
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
01:14pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?
10:49am, Wednesday, 22'nd Jun 2022
Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term
Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil
11:30am, Friday, 17'th Jun 2022 GlobeNewswire Inc.
Recent Company Submission in Response to FDA Request Extends PDUFA Date Recent Company Submission in Response to FDA Request Extends PDUFA Date
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS
11:30am, Thursday, 16'th Jun 2022 GlobeNewswire Inc.
Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H 2022 Managed Access Program for People Who Have Completed Prior Cytokinetics ALS Trials to Begin in 2H
Cytokinetics Announces Additional Data From REDWOOD-HCM Presented at the American Society of Echocardiography 33rd Annual Scientific Sessions
11:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Echocardiographic Data Show Treatment with Aficamten for 10 Weeks Results In Improved Cardiac Structure, Myocardial Relaxation and Mitral Valve Mechanics
